EXOZ

8-K - EXOZYMES INC. (0002010788) (Filer)

4 - EXOZYMES INC. (0002010788) (Issuer)

LOS ANGELES, CA / ACCESS Newswire / April 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced that Chief Commercial Officer, Damien Perriman was featured on the latest episode of the industry leading Grow Everything podcast to discuss the company's first spinout, NCTx, and how eXoZymes is building a repeatable commercialization model for high-value natural products.The Grow Everything podcast is co-hosted by biotech experts, Erum Azeez Khan and Karl Schmieder. Previous episodes have featured guests - including key individuals from companies like NVIDIA, P&

424B5 - EXOZYMES INC. (0002010788) (Filer)

4 - EXOZYMES INC. (0002010788) (Issuer)

3 - EXOZYMES INC. (0002010788) (Issuer)

4 - EXOZYMES INC. (0002010788) (Issuer)

4 - EXOZYMES INC. (0002010788) (Issuer)

4 - EXOZYMES INC. (0002010788) (Issuer)

4 - EXOZYMES INC. (0002010788) (Issuer)

Management to Host Conference Call Today at 5:30 PM EasternLOS ANGELES, CA / ACCESS Newswire / March 31, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - provides an update on operations through the fiscal year ended December 31, 2025.Michael Heltzen, CEO of eXoZymes, states, "We've moved beyond our 'big idea' potential and into execution - building differentiated assets and capabilities in a capital-efficient way that we believe sets us apart. We expect to see further value generating inflection points as programs like NCT and our cannabinoid initiatives continue to

Addison, TX, March 31, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-defining disruptive technology companies, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025. More Detailed Information 2025 Annual Shareholder Letter HERE. Form 10-K HERE. Key Assets and Strategic Developments eXoZymes (NASDAQ:EXOZ): MDB holds approximately 4.1 million shares and warrants, valued at approximately $30 million based on March 30, 2026 market prices. The company is advancing cell-free biomanufacturing with large, ownable opportunities and clear commercialization

8-K - EXOZYMES INC. (0002010788) (Filer)

10-K - EXOZYMES INC. (0002010788) (Filer)

LOS ANGELES, CA / ACCESS Newswire / March 25, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Tuesday, March 31, 2026 at 5:30 PM Eastern Time to discuss its results for the fourth quarter and full year 2025. A press release detailing these results will be issued prior to the call.CEO of eXoZymes, Michael Heltzen, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period.Investors can pre

LOS ANGELES, CA / ACCESS Newswire / March 18, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced an important validation and de-risking milestone for its cell-free biomanufacturing platform: An independent partner, Cayman Chemical, successfully ran eXoZymes' technology at pilot scale and achieved results consistent with - and in some cases exceeding - earlier internal runs.Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis ind

LOS ANGELES, CA / ACCESS Newswire / March 12, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced that Perriman will present a solution for scaling production of NCT, a naturally occurring small molecule currently being developed by eXoZymes for both nutraceutical and pharmaceutical applications.The presentation will focus on NCT's potential role in metabolic health and its emerging relevance in the rapidly evolving landscape of food, supplements, and longevity-focused wellness solutions.The March 18, 2026, MISTA Symposium Healthspan event in San Francisco bri

LOS ANGELES, CALIFORNIA / ACCESS Newswire / February 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes transforming abundant feedstock into valuable nutraceuticals and new medicines - announced the launch of a redesigned corporate website and updated visual identity, reflecting the company's refined strategic focus on pharmaceutical and nutraceutical markets.The update follows the company's previously communicated decision to sharpen its commercial scope toward sectors where management believes its AI-enhanced, cell-free exozyme platform may provide differentiated capabilities and long-term value creation potential. By concentrating resources on ph

8-K - EXOZYMES INC. (0002010788) (Filer)

N-trans-caffeoyltyramine (NCT) is an interesting naturally occurring compound that has attracted scientific attention in exploratory studies related to lipid metabolism and energy utilization pathways.The production was executed by an external partner under pilot-scale conditions using standardized protocols.The pilot run achieved approximately 99% reaction conversion, 90% isolated yield, and 535 grams of NCT at 99.6% pharma-grade purity.Reaction performance was observed to improve at increased operating scale.High-purity NCT now available for formulation development with commercial partners.LOS ANGELES, CA / ACCESS Newswire / January 29, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes"

EFFECT - EXOZYMES INC. (0002010788) (Filer)

S-3 - EXOZYMES INC. (0002010788) (Filer)

S-8 - EXOZYMES INC. (0002010788) (Filer)

LOS ANGELES, CALIFORNIA / ACCESS Newswire / December 11, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - announced the successful achievement of a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production process using its proprietary exozyme-based, cell-free biomanufacturing platform. This effort, with a conversion level of over 99% from feedstock to product, marks a major milestone in the scalability of the exozymes platform."Scaling a complex biocatalytic reaction by 100× while sustaining high feedstock conversion strengthens our belief that exozymes will for

Management to host Q3 2025 update at 5:00PM Eastern Time, today. LOS ANGELES, CALIFORNIA / ACCESS Newswire / November 13, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - plans to host a webinar at 5:00 PM Eastern Time to provides an update on operations through the fiscal quarter that ended October 31, 2025.Michael Heltzen, CEO of eXoZymes, states, "Since our last quarterly update, we have worked diligently on maturing our core assets - both scientifically as well as commercially - including what the ideal go-to market strategies are for each of these. We look forward to